Last edition
News about
Pfizer Secures EC Approval to Expand Hympavzi Use for Haemophilia Patients with Inhibitors
Pfizer has secured European Commission approval to expand the use of Hympavzi for haemophilia A and B patients with inhibitors, offering a once-weekly subcutaneous treatment option designed to reduce bleeding episodes and improve disease management.
Fosun Pharma and AriBio Sign Global Deal for AR1001 to Treat Alzheimer's
Fosun Pharma and AriBio signed an exclusive global option agreement for AR1001, an investigational Alzheimer’s disease treatment, with a USD 60 million option fee.
Shilpa Medicare Signs Long-Term Manufacturing and Development Pact with NXI Therapeutics AG
Shilpa Medicare and NXI Therapeutics AG have entered into a long-term agreement to support development and commercial manufacturing of immunomodulatory therapies, expanding Shilpa’s global CDMO footprint in high-growth biologics and specialty therapeutics.
AskBio Doses First Participant in Phase 1/2 Trial for Pompe Disease Gene Therapy
AskBio has dosed the first participant in its Phase 1/2 PROGRESS-GT LOPD trial evaluating investigational gene therapy AB-1009 for late-onset Pompe disease, advancing research into potential long-term treatment solutions for the rare genetic disorder.
Novo Nordisk Higher-Dose Wegovy Shows 28 Percent Weight Loss in Early Responders
Novo Nordisk reports new analyses showing higher-dose Wegovy helped early responders achieve up to 28 percent weight loss, highlighting its effectiveness for obesity treatment regardless of response speed.
FDA Advances Drug Repurposing to Address Unmet Medical Needs
US Food and Drug Administration (FDA) is advancing drug repurposing to accelerate treatments for chronic and rare diseases, addressing unmet medical needs with faster, cost-effective innovation.
Roche Receives CE Mark for Blood-Based Alzheimer's Diagnostic Test
Roche receives CE Mark approval for Elecsys pTau217, a blood-based Alzheimer’s diagnostic test developed with Eli Lilly, aimed at enabling earlier and less invasive detection of amyloid pathology in patients with cognitive decline.
Bristol Myers Squibb and Hengrui Pharma collaborated to jointly develop 13 early-stage programmes across oncology, haematology and immunology, with a potential deal value of up to USD 15.2 billion.
Coya Therapeutics Wins FDA Fast Track for COYA 302 in Amyotrophic Lateral Sclerosis
Coya Therapeutics receives US Food and Drug Administration (FDA) Fast Track designation for COYA 302, an investigational biologic therapy for Amyotrophic Lateral Sclerosis (ALS).
Insilico Medicine and Ribo Partner on AI-Powered RNA Therapeutics Development
Insilico Medicine and Ribo partner to accelerate RNA interference and oligonucleotide drug development using Artificial Intelligence (AI)I-powered discovery platforms and automated laboratory technologies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy